Rofecoxib

Drugs

Volumn 58, Issue 3, 1999, Pages 499-505

  Scott, Lesley J ^a   Lamb, Harriet M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTACID AGENT; CIMETIDINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIGOXIN; IBUPROFEN; INDOMETACIN; KETOCONAZOLE; MELOXICAM; METHOTREXATE; NABUMETONE; NAPROXEN; ORAL CONTRACEPTIVE AGENT; PREDNISOLONE; PREDNISONE; RIFAMPICIN; ROFECOXIB; UNCLASSIFIED DRUG; WARFARIN;

ANALGESIA; ANTIPYRETIC ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DYSMENORRHEA; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PAIN; PHARMACODYNAMICS; REVIEW; RHEUMATOID ARTHRITIS; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION;

ANALGESICS; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DYSMENORRHEA; ENZYME INHIBITORS; HUMANS; LACTONES; OSTEOARTHRITIS; SULFONES;

EID: 0032885911     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958030-00016     Document Type: Review

References (31)

1. Lane NE, Thompson JM. Management of osteoarthritis in the primary-care setting: an evidence-based approach to treatment. Am J Med 1997; 103 (6A): 25S-35
2. Creamer P, Hochberg MC. Osteoarthritis. Lancet 1997; 350: 503-9
3. Bollen WW. Scientific rationale for specific inhibition of COX-2. J Rheumatol 1998 May; 25 Suppl. 51: 2-7
4. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997; 24 Suppl. 49: 6-8
5. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterisation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999; 65: 336-47
6. Van Hecken A, Depre M, Ehrich E, et al. Demonstration of specific COX-2 inhibition by MK-966 in humans with supratherapeutic doses. [abstract no. PII-69]. Clin Pharmacol Ther 1999; 65 (2): 164
7. Schwartz, JI, Van Hecken A, De Lepeleire I, et al. Comparative inhibitory activity of rofecoxib (MK-0966), Vioxx™, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 vs COX-1 in healthy female volunteers [abstract no. 857]. In: XIV European League Against Rheumatism Congress: 1999 Jun 6-11; Glasgow
8. Lanza F, Simon T, Quan H, et al. Selective inhibition of cyclooxygenase-2 with MK-0966 (250 mg q.d.) is associated with less gastroduodenal damage than aspirin 650 mg q.i.d. or ibuprofen 800 mg t.i.d [abstract]. Gastroenterology 1997; 112 Suppl.: 194
9. Bjarnson I, Sigthorsson G, Crane R, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg q.d. does not increase intestinal permeability: a controlled study with placebo and indomethacin 50 mg t.i.d [abstract 246]. Am J Gastroenterol 1998 Sep; 93: 1670
10. Hunt R, Bowen B, James C, et al. COX-2 specific inhibition with MK-0966 25 or 50 mg q.d. over 4 weeks does not increase fecal blood loss: a controlled study with placebo and ibuprofen 800 mg t.i.d [abstract 247]. Am J Gastroenterol 1998 Sep; 93: 1671
11. Schwartz J, Mukhopadhyay S, McBride K, et al. Antipyretic activity of a selective cyclooxygenase-2 inhibitor. MK-0966 [abstract PI-123]. Clin Pharmacol Ther 1998 Feb; 63: 167
12. Merck and Co, Inc. Vioxx™ prescribing in formation. New Jersey, USA, 1998
13. Ehrich E, Schnitzer T, Kivitz A, et al. MK-966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study [abstract 330]. Arthritis Rheum 1997 Sep; 40 Suppl.: 85
14. Cannon G, Caldwell J, Holt P, et al. MK-0966, a specific cox-2 inhibitor, has clinical efficacy comparable to diclofenae in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial [abstract no. 983]. Arthritis Rheum 1998 Sep; 41 Suppl.: S196
15. Saag K, Fisher C, Mekay J, et al. MK 0966, a specific cox-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial [abstract no. 984]. Arthritis Rheum 1998 Sept; 41 Suppl: S196
16. Day R, Luza A, Casteneda O, et al. Rofecoxib, a COX-2 specific inhibitor (C-2 SI), had clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial [abstract no.860]. In: XIV European League Against Rheumatism Congress: 1999 Jun 6-11; Glasgow
17. Truitt K, Ettinger W, Schnitzer T, et al. Rofecoxib, a COX-2 specific inhibitor, had clinical efficacy and overall safety in treating osteoarthritis patients 80 years and older [abstract no. 859]. In: XIV European League Against Rheumatism Congress: 1999 Jun 6-11; Glasgow
18. Mehlisch DR, Mills S, Sandler M, et al. Ev vivo assay of COX-2 inhibition predicts analgesic efficacy in post-surgical dental pain with MK-966 [abstract]. Clin Pharmacol Ther 1998 Feb; 63: 139
19. Fricke J, Morrison BW, Fite S, et al. Mk-966 versus naproxen sodium 550mg in post-surgical dental pnin [abstract no. PI-7]. Clin Pharmacol Ther 1999; 65 (2): 119
20. Brown J, Morrison BW, Christensen S, et al. MK-0966 50mg versus ibuprofen 400mg in post-surgical dental pain [abstract PI-4]. Clin Pharmacol Ther 1999; 65 (2): 118
21. Brown J, Morrison BW, Bitner M, et al. The COX-2 specific inhibitor, MK-0966, is effective in the treatment of primary dysmenorrhea [abstract no. PI-5]. Clin Pharmacol Ther 1999; 65 (2): 118
22. Daniels S, Morrison BW, Cantu N, et al. Dose ranging trial of the effect of MK-966 in primary dysmenorrhea [abstract no. PI-6]. Clin Pharmacol Ther 1999; 65 (2): 118
23. Hawkey CJ. COX-2 inhibitors. Lancet 1999 Jan 23; 353: 307-14
24. Langman M, Jensen D, Harper S, et al. Lower incidence of clinically evident upper-GI perforations, ulcers and bleeds in patients treated with rofecoxib versus nonspecific cyclooxygenase inhibitors [abstract no. G1008]. Gastroenterology 1999; 116 Pt 2: A232
25. Hawkey C, Laine L, Mortensen E, et al. Treatment of osteoarthritis with rofecoxib, a cyclooxygenase-2 (COX-2) specific inhibitor, was associated with a lower incidence of gastroduodenal ulcers compared to ibuprofen and was comparable to placebo treatment [abstract no. 861]. In: XIV European League Against Rheumatism Congress: 1999 Jun 6-11; Glasgow
26. Schwanz JI, De Smet M, Larson P, et al. Influence of the selective cyclooxygenase-2 inhibitor, MK-0966 (MK), on digoxin (DG) serum concentrations [abstract no. P52.9]. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 Suppl. 2: R510
27. Schwartz J, Hsieh P, Ebel D, et al. Influence of a selective cyclooxygenase-2 inhibitor, MK-0966, on ethinyl estradiol and norethindrone serum concentrations [abstract B25]. Eur J Clin Pharmacol 1997; 52 Suppl.: 113
28. Schwartz JI, Waldman S, Slaughter D, et al. Influence of the selective cyclooxygenase-2 inhibitor, MK-0966, on cytochrome P450 (CYP) activity [abstract no. P.52.R]. Naunyn Schmiedebergs Arch Pharmacol 1998; 358 Suppl. 2: R509
29. Schwartz J, Porras A, Larson P, et al. Influence of antacids on the bioavailability (F) of a specific cyclooxygenase (COX)-2 inhibitor, MK-0966 (M) in the elderly [abstract no. PII-104]. Clin Pharmacol Ther 1999; 65 (2): 173
30. Greenberg HE, Gillen LP, Dorval EP, et al. MK-0966, a cyclooxygenase-2 (COX-2) specific inhibitor, had no effect on the anti-platelet activity of low-dose aspirin (ASA) measured by serum thromboxane B2 (TXB2) production and platelet aggregation [abstract no. PII-66]. Clin Pharmacol Ther 1999; 65 (2): 163
31. Schwartz JI, Mukhopadhyay S, Porras AG, et al. Influence of a selective cyclooxygenase-2 (COX-2) inhibitor, rofecoxib (MK-0966, Vioxx™, on prednisone and prednisolone plasma concentrations [abstract no. 856]. In: XIV European League Against Rheumatism Congress: 1999 Jun 6-11; Glasgow